Pancreatic cancer remains a difficult disease to treat and is expected to be the second leading cause of U.S. cancer-related deaths by 2030. Researchers hope clinical trials and insights into the genetics of the disease will reverse the trend.

by Kendall K. Morgan

Policy Matters

Cancer outcomes are changing for the better, but advances are not affecting all patients equally.

by Brian Rivers, PhD

The National Cancer Institute and the Food and Drug Administration have provided guidance for managing clinical trials amid the spread of the novel coronavirus. Cancer centers are making changes to care for some patients enrolled in trials.

by Anna Azvolinsky

Cancer patients in the U.S. are feeling impacts from the new coronavirus.

by Kate Yandell

Multigene panels that rely on next-generation sequencing are increasingly used to test for hereditary cancer risk-related mutations. The federal government aims to expand Medicare coverage for these tests.

by Ashley P. Taylor

Using an older method of prostate biopsy together with MRI-targeted biopsy more accurately diagnoses prostate cancer than either method alone, a study finds.

by Kate Yandell

A study illuminates the alcohol consumption habits of cancer survivors.

by Jen Tota McGivney

Medical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.

by Anna Azvolinsky

Melvin Mann benefited from joining a pivotal clinical trial for chronic myelogenous leukemia, but participation came with logistical challenges.

by Melvin Mann

Letting children know they might have a mutation that increases their risk for cancer can be a challenge for patients. Experts stress there is no right or wrong way to share the information.

by Marci A. Landsmann